United States / English

EMD Millipore is now MilliporeSigma

Advance Biotech Grant Program

Unlock your molecule's potential.

Apply to our USA/Canada Advance Biotech Grant Program Today!

We understand the challenges biotech companies face in the quest to push their biological drug candidates to market. We are hosting our Advance Biotech Grant Program, the 6th edition, open to US and Canadian biotech companies, to help you accelerate to clinic faster.

Apply now for a chance to win.


$200,000 awarded in products to biotech companies with molecules under development.

  • First Prize: $100k **
  • Second Prize: $60k **
  • Third Prize: $40k **

How to Apply

Please submit a completed application before 31st March 2019. Winners will be announced in April 2019.

Submit Application

Official Rules

[** in products ]

To learn more on how we can help you accelerate your biotech drug development, watch this testimonial from Kilian Guse, PhD. CEO, Co-Founder GeneQuine Biotherapeutics, and recipient of the 2016 Advance Biotech Grant Program.

Questions? Contact us.

If you need more information, leave your details and we will contact you.

More Info

Application submissions will be judged by a qualified Merck KGaA, Darmstadt, Germany panel of judges, based on the following objective criteria of equal weight: (i) the scientific and societal merit of the therapy being developed, and (ii) process challenges and expertise gaps associated with the development of the therapy. See official program rules for full details. Note. The closing date for submission of Grant applications is midnight on 30th September 2016. Each Application received by midnight on 30th June 2016 will also have the chance to win an iPad tablet. Please refer to the official rules for the Grant and to win an iPad® tablet. Winner selected, informed and announced on or around 15th November 2016.

Biotech Resource Hub: Stay Current

Advance Biotech Grant Program – Accelerating Therapeutic Development in Life Science

The Life Science business of MilliporeSigma is expanding its commitment to the global biotech community with its Advance Biotech Grant Program. Through the newly expanded grant program, every six months, three recipients around the globe will be awarded a total of €200,000 in free services and products to address their process development challenges. In total, six companies will benefit from the Advance Biotech Grant Program each year. Press Release

The Advance Biotech Grant Program (USA and Canada) is launching 01 November 2018.
Read more about the Advance Biotech Grant Program.

Find out more about our programs:

Bringing your molecule to market. As part of our commitment to meet the needs of the life science community, we’ve developed several programs that recognize stand-out emerging biotech companies. These programs are designed to support biotech start-ups and medium sized companies in solving their current bioprocess development challenges to bring the next generation of molecules to market.

More details about EB Programs>

WEBINAR: Accelerated ADC Development with Integrated Supply Chain Solutions

Learn more about the advantages to work with one source on your mAb, linker/ payload supplies and conjugation services.

Watch Now >

WEBINAR: RNA Based Therapeutics and Vaccines: Bioprocessing Technology Trends

Review the current dynamics in the RNA therapeutics/vaccines market with a focus on process development and manufacturing strategies.

Watch this Webinar >

WEBINAR: Managing Process Scale-up and Tech Transfer

Learn more on points to consider for successful tech transfers with a focus on cGMP training requirements.

Watch this Webinar >

Webinars On-Demand >

WHITE PAPER: 2017 Life Science Executive Summit

Establishing an open dialog within the biotech community....

Read more and download >

The Changing Biopharma Risk Equation

A report from the The Economist Intelligence Unit sponsored by MilliporeSigma.
This paper, which incorporates the results of a survey of 254 pharmaceutical executives from around the world and a range of interviews with industry experts, explores in detail global pharmaceutical companies' growth strategies and their plans for managing the associated risks.

Read the study >

Contact Us

Research. Development. Production.

We are a leading supplier to the global Life Science industry: solutions and services for research, development and production of biotechnology and pharmaceutical drug therapies.

© 2017 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.
EMD Millipore is a part of Merck KGaA, Darmstadt, Germany.